What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing CJC-1295 + Ipamorelin inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
The CJC-1295 + Ipamorelin combination is one of the most-requested GH-axis blends in the catalog and one of the most-cited dual-pathway formulations in compounding pharmacy and research workflows. The two peptides act on parallel signaling pathways that converge on somatotroph GH release: CJC-1295 (no DAC, the Modified GRF 1-29 form) is a GHRH-receptor agonist mimicking the hypothalamic GHRH input, while Ipamorelin is a selective GHSR (ghrelin receptor) agonist mimicking the alternative ghrelin-pathway input. The dual-pathway combination produces GH-release magnitudes substantially larger than either component alone at comparable individual doses, the synergy is the entire rationale for the combination. PeptideXpo supplies the CJC-1295 + Ipamorelin blend as a co-lyophilized vial at ≥99.0% HPLC purity for each component. The standard ratio is 1:1 by mass (5+5 mg in a 10 mg vial); custom ratios (2+5, 5+10, 10+10) and larger total fills are available through the OEM service. Co-lyophilization is preferred over solution-phase mixing because both components are short-half-life peptides where ratio stability matters operationally and the co-lyophilized form locks the ratio at the lyophilization step. The release packet certifies both component purities individually plus the actual ratio in the released vial.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: 503A / 503B compounding pharmacies and medical aesthetic clinics and med spas.
Specifications
Documentation available on request
Regulatory note
Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Component-level analytical data is supplied for every batch.
Frequently asked questions
The combination works because the two components engage different receptors that converge on the same target cell type. CJC-1295 (no DAC) activates the GHRH receptor on anterior-pituitary somatotrophs; Ipamorelin activates the GHSR (ghrelin) receptor on the same cells. The two signaling cascades reinforce rather than compete, producing GH-release magnitudes substantially larger than either alone, typically 4-5× larger acute GH pulse at comparable individual doses. For the full pharmacology rationale, ratio considerations, and analytical-packet specifics, see our [CJC-1295 + Ipamorelin guide](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide).
Yes, all three are GHRH-receptor agonists and produce mechanistically equivalent dual-pathway combinations when paired with Ipamorelin. The Tesamorelin + Ipamorelin blend (tesa-ipa-blend SKU) is supplied at a 10+5 mg ratio reflecting the higher mass-equivalent dosing typical for Tesamorelin. Sermorelin + Ipamorelin is less common in commercial blends because Sermorelin's shorter half-life is less well-matched to Ipamorelin's pharmacokinetics. The CJC-1295 (no DAC) + Ipamorelin pairing remains the most-requested combination because the half-life profiles complement each other best.
Related peptides
Modified GRF 1-29 · GHRH analog
Ghrelin / GHSR pathway GH-release peptide
29-mer
GHRH 1-29 fragment
